Cd38 as a biomarker and biotarget in cell-lymphomas

T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sézary syndrome are the most frequent cutaneous T-cell lymphomas. Now the inventors showed the expression of CD38 by Sézary cells and in CD4+ blood cells of patients with Sezary syndrome. CD38 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CD38-expressing cancer cells would eliminate tumor cells.

Keywords: cutaneous T-cell lymphoma, Sézary syndrome, Diagnostic, Treatment Response Prediction, Prognosis CD38
Patent Application number: EP 22 305 106.1 on 31/01/2022
PCT/EP2023/052000 on 30/01/2023
J Invest Dermatol 2023 Jan 28 Ta et al. CD38 Targeting in Aggressive Treatment-Refractory Cutaneous T-Cell Lymphomas doi: 10.1016/j.jid.2023.01.009. Online ahead of print.

You might also be interested in


Inserm Transfert

Research tool licensing team